The mechanisms leading to neuronal death in neurodegenerative disease are poorly understood. Many of these disorders, including Alzheimer's, Parkinson's and prion diseases, are associated with the accumulation of misfolded disease-specific proteins. The unfolded protein response is a protective cellular mechanism triggered by rising levels of misfolded proteins. One arm of this pathway results in the transient shutdown of protein translation, through phosphorylation of the a-subunit of eukaryotic translation initiation factor, eIF2. Activation of the unfolded protein response and/or increased eIF2a-P levels are seen in patients with Alzheimer's, Parkinson's and prion diseases [1] [2] [3] [4] , but how this links to neurodegeneration is unknown. Here we show that accumulation of prion protein during prion replication causes persistent translational repression of global protein synthesis by eIF2a-P, associated with synaptic failure and neuronal loss in prion-diseased mice. Further, we show that promoting translational recovery in hippocampi of prion-infected mice is neuroprotective. Overexpression of GADD34, a specific eIF2a-P phosphatase, as well as reduction of levels of prion protein by lentivirally mediated RNA interference, reduced eIF2a-P levels. As a result, both approaches restored vital translation rates during prion disease, rescuing synaptic deficits and neuronal loss, thereby significantly increasing survival. In contrast, salubrinal, an inhibitor of eIF2a-P dephosphorylation 5 , increased eIF2a-P levels, exacerbating neurotoxicity and significantly reducing survival in priondiseased mice. Given the prevalence of protein misfolding and activation of the unfolded protein response in several neurodegenerative diseases, our results suggest that manipulation of common pathways such as translational control, rather than disease-specific approaches, may lead to new therapies preventing synaptic failure and neuronal loss across the spectrum of these disorders.
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Neurodegenerative diseases pose an ever-increasing challenge for society and health care systems worldwide, but their molecular pathogenesis is still largely unknown and no curative treatments exist. Alzheimer's (AD), Parkinson's (PD) and prion diseases are separate clinical and pathological conditions, but it is likely they share common mechanisms leading to neuronal death. Mice with prion disease show misfolded prion protein (PrP) accumulation and develop extensive neurodegeneration (with profound neurological deficits), in contrast to mouse models of AD or PD, in which neuronal loss is rare. Uniquely therefore, prion-infected mice allow access to mechanisms linking protein misfolding with neuronal death. Prion replication involves the conversion of cellular PrP, PrP C , to its misfolded, aggregating conformer, PrP Sc , a process leading ultimately to neurodegeneration 6 . We have previously shown rescue of neuronal loss and reversal of early cognitive and morphological changes in prion-infected mice by depleting PrP in neurons, preventing prion replication and abrogating neurotoxicity [7] [8] [9] . However, the molecular mechanisms underlying both the progression of disease, and those underlying recovery in PrP-depleted animals, were unknown.
To understand these processes better, we now analysed the evolution of neurodegeneration in prion-diseased mice. We examined hippocampi from prion-infected tg37 mice used in our previous experiments [7] [8] [9] [10] , in which the time course of impairment and recovery are clearly defined. Hemizygous tg37 mice express mouse PrP at approximately three times wild-type levels and succumb to Rocky Mountain Laboratory (RML) prion infection within 12 weeks post infection (w.p.i.) 10 . They first develop behavioural signs with decreased burrowing activity at approximately 9 w.p.i., after reduction in hippocampal synaptic transmission and first neuropathological changes 7, 8 . This is the window of reversibility when diseased neurons can still be rescued: PrP depletion up to 9 w.p.i., but not later, rescues neurotoxicity, as by 10 w.p.i. neuronal loss is established [7] [8] [9] . We measured PrP levels, synapse number, levels of synaptic proteins and synaptic transmission in prion-infected mice weekly from 5 w.p.i., and burrowing behaviour from 6 w.p.i. We examined brains histologically and counted CA1 neurons. (Cohorts of at least 30 animals were used per group; biochemical and histological analyses were done on three mice per time point, burrowing behaviour on 12, n for other analyses is indicated in figure legends.) We found an early decline in synapse number in asymptomatic animals at 7 w.p.i. to approximately 55% of control levels (Fig. 1a) , despite unchanged levels of several pre-and postsynaptic marker proteins (Fig. 1b) . Reduced synapse number with normal synaptic protein levels is likely to reflect impaired structural plasticity of synapses at this early stage of disease. At 9 w.p.i., however, there was a sudden decline in synaptic protein levels to approximately 50% of control levels for several pre-(SNAP-25 and VAMP-2) and postsynaptic (PSD-95 and NMDAR1) proteins (Fig. 1b and Supplementary Fig. 1b ). This was associated with further decline in synapse number, and the critical reduction in synaptic transmission, both in amplitude of evoked excitatory postsynaptic currents (EPSCs) and in the number of spontaneous miniature EPSCs (mEPSCs) in CA1 neurons ( Fig. 1c and Supplementary Fig. 1e ). This was coincident with behavioural change (Fig. 1d ) and first spongiform pathology ( Supplementary Fig. 1d ), and was rapidly followed by the onset of neurodegeneration, resulting in 50% reduction in hippocampal pyramidal neurons at 10 w.p.i. (Fig. 1e) . All animals developed overt motor signs and were terminally sick by 12 w.p.i.
The abrupt loss of synaptic proteins at 9 w.p.i. appeared to be a critical factor in the evolution of disease, occurring when synapse number and transmission were already declining. This could result from increased degradation, or decreased synthesis. Prion infection in mice is known to impair the ubiquitin proteasome system, causing reduction-not increase-in protein degradation 11 . We therefore asked if protein synthesis was reduced through translational control mechanisms. Given that total PrP levels rise during disease (Fig. 2a) , and that PrP is synthesized in the endoplasmic reticulum, we examined the translational repression pathway of the unfolded protein response (UPR). Rising levels of unfolded proteins detected by BiP/Grp78 (BiP) in the endoplasmic reticulum membrane cause auto-phosphorylation of protein kinase-like endoplasmic reticulum kinase (PERK). PERK-P phosphorylates eIF2a, which blocks the initiation step of translation, reducing new protein synthesis 12 . eIF2a-P then induces ATF4 and CHOP expression, ultimately leading to caspase-12 cleavage, and expression of GADD34, the stress-induced eIF2a-P-specific phosphatase and key effector of a negative feedback loop that terminates UPR signalling, allowing translational recovery (Fig. 2g) .
Upregulation of various steps in the pathway are seen in human prion cases 13, 14 and in prion-infected mice 13 ; and increased phosphorylation of eIF2a occurs in AD and PD [1] [2] [3] [4] . We characterized this pathway in prion-diseased mice. We found that PERK-P and eIF2a-P increased throughout the course of disease (Fig. 2b, c and Supplementary  Fig. 2b-d ), in parallel with rising levels of total PrP, and the presence of detectable protease-resistant PrP Sc (Fig. 2a) . GADD34 levels did not change, despite rising eIF2a-P levels, suggesting insufficient GADD34 for dephosphorylation of increased eIF2a-P ( Fig. 2d and Supplementary  Fig. 2e ). Caspase-12 cleavage occurred at 10 w.p.i., following rising CHOP expression (Fig. 2e, f) , coincident with onset of neuronal loss ( Fig. 1e ; see also Hetz et al.
13
). However, the exact effector mechanism of neuronal death is unclear: we found neither apoptosis, nor autophagy nor necrosis on examination of hippocampal slices ( Supplementary  Fig. 3 ); and neither Bax deletion, nor Bcl-2 overexpression 15 nor caspase-12 deficiency 16 is neuroprotective in prion disease. We asked what effects the marked rise in eIF2a-P levels at 9 w.p.i. had on overall protein synthesis in hippocampi. We found abrupt, Sc levels (detected by addition of proteinase K (PK)) increase during prion infection; b, PERK-P and c, eIF2a-P levels, rise during disease; d, GADD34 levels do not change but e, CHOP levels increase, throughout disease and f, caspase-12 is cleaved at 10 w.p.i. g, Scheme depicting the translational repression pathway of the UPR showing points for intervention by LV-shPrP, LV-GADD34 and salubrinal. Activation of the pathway results in reduction of global translation at 9 w.p.i. (Fig. 2h) , confirming sudden onset of reduced protein synthesis. We also looked at translation of specific messenger RNA (mRNAs). We extracted polysomes from hippocampi of prion-infected mice. In successive polysomal fractions, mRNAs are associated with increased numbers of actively translating ribosomes. The change from a single fraction to the next reflects a large change in translation rate for any specific mRNA. Polysomal profiles at 9 w.p.i. showed a reduction in the overall number of actively translating ribosomes, represented by the smaller area under the curve between fractions 6-11 in prion-infected mice (Fig. 2i) . Northern blots for specific mRNAs in individual polysomal fractions confirmed changes in actively translated messages ** ** Figure 3 | Preventing eIF2a-P formation or promoting its dephosphorylation in prion-diseased mice rescues synaptic failure and neuronal loss, while increased eIF2a-P levels exacerbate neurotoxicity. a, Mice were infected with RML prions and treated with salubrinal (blue) or stereotaxically injected with lentiviruses expressing anti-PrP shRNA (LVshPrP; green), GADD34 (LV-GADD34; pink) or no insert (LV-control; grey) into both hippocampi. Control groups received no virus (prion only; black) or normal brain homogenate (control; white). Mice were tested at 9 w.p.i. b, LVshPrP reduced total PrP and prevented UPR induction, reducing levels of PERK-P (c) and eIF2a-P (d). LV-GADD34 reduced eIF2a-P despite PERK-P induction, and salubrinal increased eIF2a-P. e, Both LV-GADD34 and LVshPrP prevented reduction in global translation at 9 w.p.i., but salubrinal reduced translation rates even further. f, LV-GADD34 and LV-shPrP reversed prion-induced eIF2a-P-mediated translational changes of specific mRNAs in polysomal fractions shown on northern blots. g, Synaptic protein levels, h, synaptic transmission, i, burrowing behaviour and j, synapse number were protected by GADD34 treatment and PrP knockdown. Salubrinal exacerbated protein loss. Representative electron micrographs (arrowheads denote individual synapses) and quantification are shown (n 5 2 mice, 32 slices per mouse for each analysis). k, LV-GADD34 and LV-shPrP resulted in extensive neuroprotection of hippocampal CA1 pyramidal neurons and spongiosis (haematoxylin and eosin stained sections) and chart, right, when the animals were dying of scrapie at nearly 14 w.p.i. Salubrinal accelerated neurodegeneration with extensive neuronal loss seen at 9 w.p.i., earlier than in prion-sick animals at 12 w.p.i. Scale bar, 50 mm and 2 mm for electron micrographs. All data in bar charts show mean 6 s.e.m. One-way ANOVA with Tukey's post-test was used for multiple comparisons; *P , 0.05; **P , 0.005; ***P , 0.0001. For all experiments n 5 3 mice, unless otherwise stated. All controls were at 9 w.p.i. LETTER RESEARCH consistent with eIF2a-P induction. Thus SNAP-25 and b-actin mRNAs showed a left shift to a lower polysomal fraction (Fig. 2j) , representing reduced active translation (Fig. 1b) . In contrast, ATF4 mRNA (which escapes eIF2a-P-mediated inhibition of translation, owing to the presence of upstream open reading frames in its 59 untranslated region (UTR) 17, 18 ), showed increased active translation, represented by a right shift to a higher polysomal fraction (Fig. 2j and Supplementary Figs 4  and 5) . PrP mRNA did not show reduced translation, possibly because of the existence of similar translational control elements within the PrP gene. Indeed, human PrP mRNA has multiple upstream AUG upstream open reading frames in its 59 UTR, which could allow it to escape eIF2a-P translational inhibition in the same way as ATF4 does 17, 18 ( Supplementary Fig. 6 ). Overall, these findings confirm that reduction in protein synthesis in prion disease is controlled at the translational, not the transcriptional, level, as it is rates of translation, not levels of total mRNA, that change (Supplementary Figs 1c and 2g, h) .
We propose that the key trigger to prion neurodegeneration is the continued, unchecked activation of the UPR due to rising levels of PrP during disease, with fatal repression of translation rates. Importantly, prion neurotoxicity relates in a dose-dependent manner to PrP expression [19] [20] [21] . We therefore asked if levels of eIF2a-P and onset of neurodegeneration were related to levels of PrP in different strains of mice. We found that in homozygous tg37 mice, which overexpress PrP approximately sixfold, eIF2a-P was induced at 6 w.p.i., and mice succumbed to prion infection at approximately 8 w.p.i. In wild-type C57/Bl6 mice, which express 13 levels of PrP, eIF2a-P was induced at 16 w.p.i. and animals succumbed at approximately 22 w.p.i. Thus, as for hemizygous tg37 mice where PrP was expressed at three times wildtype levels and eIF2a-P was induced at 9 w.p.i. followed by death at 12 w.p.i. (Fig. 2c) , in each case there was a corresponding critical decline in synaptic proteins and synapse number after eIF2a-P induction ( Supplementary Fig. 7 and Fig. 1a, b) .
Transient eIF2a phosphorylation is beneficial to cells overloaded with misfolded proteins: it reduces protein synthesis and increases availability of chaperones, promoting refolding 22, 23 . However, persistently high levels of eIF2a-P are detrimental in vitro 24 . To test directly the role of eIF2a-P in prion neurodegeneration in vivo, we first asked if reduction of eIF2a-P levels in prion disease would be neuroprotective. We used two approaches. We overexpressed GADD34, the eIF2a-Pspecific phosphatase to reduce eIF2a-P levels directly. In a separate experiment, we used targeted RNA interference of PrP to abrogate UPR activation and prevent eIF2a-P formation. We then asked if increased levels of eIF2a-P exacerbate prion neurotoxicity by using salubrinal, a specific small-molecule inhibitor of eIF2a-P dephosphorylation 5 , in infected mice. Salubrinal penetrates the blood-brain barrier ( Supplementary Fig. 8 ) and has been used for modulation of eIF2a-P-dependent effects in endoplasmic reticulum stressmediated processes in the central nervous system in vivo after peripheral administration [25] [26] [27] . Mice were inoculated with prions and received hippocampal injections of lentiviruses expressing GADD34 (LV-GADD34), anti-PrP shRNA (LV-shPrP) or yellow fluorescent protein (YFP) only (LV-control) at 5 w.p.i., allowing 4 weeks for lentiviral expression to occur, before testing the effects of treatment on eIF2a-P levels and neurotoxicity at 9 w.p.i. (All virally expressed constructs were driven by the CAMKII promoter for neuron-specific expression ( Supplementary Fig. 9a-c) ). Another group of prion-infected mice received daily intraperitoneal injections of salubrinal (1 mg kg 21 ), for 1 week, from 8 w.p.i., with controls receiving vehicle alone. Two further control groups received normal brain homogenate, or RML prion inoculation alone (Fig. 3a) .
We examined mice from each group at 9 w.p.i. when eIF2a-Pmediated translational repression occurs (Fig. 2c, h ). LV-GADD34 treatment did not reduce PrP levels (Fig. 3b) and PERK-P levels were equivalent to those in prion-only or LV-control treated animals ( Fig. 3c and Supplementary Fig. 9d ), confirming UPR activation in these mice. Critically, however, eIF2a-P levels were reduced (Fig. 3d and Supplementary Fig. 9e ), strongly supporting its dephosphorylation by lentivirally mediated GADD34 expression. LV-shPrP treatment reduced PrP levels (Fig. 3b) and prevented the PrP-induced rise in PERK-P and eIF2a-P seen in untreated animals (Fig. 3c, d ), confirming prevention of UPR activation. Both GADD34 overexpression and PrP knockdown prevented prion-induced eIF2a-P-mediated translational repression, with restoration of global rates at 9 w.p.i. (Fig. 3e) and prevention of eIF2a-P-induced changes in translation of specific mRNAs (Fig. 3f and Supplementary Fig. 4) . As a result, synaptic protein levels, synaptic transmission and synapse number in prion-diseased mice treated with GADD34 or PrP knockdown were protected and equivalent to levels in uninfected control mice (Fig. 3g,  h, j) . Burrowing deficits were prevented (Fig. 3i) and there was extensive neuronal protection in the hippocampus, with no neuronal loss and markedly reduced spongiform change (Fig. 3k) . Further, targeted expression of LV-GADD34 and focal PrP knockdown had a modest, but highly significant, effect on survival, increasing this to 90 6 3 days and 92 6 5 days respectively, compared with 83 6 2 days for prion-only mice (Fig. 4) , and to 82 6 2 days for LV-control injected mice ( Supplementary Fig. 10 ). For both LV-GADD34 and LV-shPrP, treatment was localized to the dorsal hippocampus, a very small area of the brain, so prion infection in the rest of the brain was fatal, but neuroprotection in GADD34-treated animals was seen even when the animals were terminally sick (Fig. 3k) . More extensive brain-wide delivery of GADD34, or targeting of this pathway, would be predicted to increase survival further and give more widespread neuroprotection. Critically, treatment with salubrinal had the opposite effect, by preventing dephosphorylation of eIF2a-P. Thus, eIF2a-P levels were markedly higher at 9 w.p.i. than in prion-only controls ( Fig. 3d and Supplementary Fig. 9e ), causing further repression of global translation (Fig. 3e) and reduction of synaptic proteins (Fig. 3g) . Salubrinal treatment resulted in earlier severe neuronal loss (Fig. 3k) , and significantly accelerated disease, compared with untreated prion-infected mice (Fig. 4) .
In conclusion, we have shown that PrP replication causes sustained UPR induction with persistent, deleterious expression of eIF2a-P in prion disease. The resulting chronic blockade of protein synthesis leads to synaptic failure, spongiosis and neuronal loss. Promoting eIF2a-P dephosphorylation rescues vital translation rates and is thereby neuroprotective, whereas preventing this further reduces translation and enhances neurotoxicity. The data support the development of generic proteostatic approaches 22, 28 to therapy-fine-tuning protein synthesis-in prion, and perhaps other neurodegenerative disorders involving protein misfolding. . Animals were culled when they developed clinical signs of scrapie. Control mice received 1% normal brain homogenate. Hippocampi were processed for protein, RNA or histological analysis [7] [8] [9] [10] . For all analyses n 5 3 mice unless otherwise stated. Lentiviruses and stereotaxic surgery. Lentiviral plasmids were generated using the Invitrogen Gateway cloning system 29 . The neuron-specific promoter CAMKII was used to drive shPrP expression, carboxy (C)-terminal GADD34 expression, or YFP alone (control virus). Viruses were injected stereotaxically into the CA1 region of the hippocampus as described 9 . Salubrinal treatment. Mice received daily intraperitoneal injections of 1 mg kg 21 of salubrinal (Calbiochem), or vehicle (diluted dimethylsulphoxide (DMSO) in saline (Sigma)) 25 , for 7 days from 8 w.p.i. Experimental analyses. Synapse numbers were counted in electron micrographs of the stratum radiatum of the hippocampal CA1 region 30 . Synaptic marker proteins, UPR pathway proteins and PrP were analysed by immunoblotting of brain homogenates. PrP Sc was detected after proteinase K digestion 7 . Whole-cell recordings were done in acute hippocampal slices to measure synaptic transmission 31 . Global translation levels were detected using [ 35 S]methionine incorporation in acute hippocampal slices; translations of specific transcripts in polysomal fractions from hippocampi were analysed by northern blotting 32 . Neuronal counts were determined by quantifying NeuN-positive pyramidal CA1 neurons 9 . All analyses were performed using hippocampi from three mice in triplicate unless otherwise stated. Burrowing behaviour was performed as described on groups of 10 or more mice 8 . Statistical analyses were performed using using GraphPad/ Prism software, version 5, using Student's t-test for data sets with normal distribution and a single intervention. Analysis of variance (ANOVA) testing was performed using one-way analysis with Tukey's post-hoc test for multiple comparisons.
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It has been brought to our attention that there is an error in Supplementary Fig. 1b , owing to incorrect assembly of the image. The correct panel and figure legend (and the raw data used to generate Supplementary  Fig. 1b) are shown in the Supplementary Information to this Corrigendum.
We would also like to clarify that the antibody used in Fig. 2e of the original Letter is Millipore mab1637. This antibody reacts with the C terminus of the neuron-specific b III isoform of b-tubulin. It does not identify b-tubulin in glial or non-neuronal cells, hence the absence of tubulin bands in control HeLa cells.
Supplementary Information is available in the online version of this Corrigendum.
